Skip to main content

Advertisement

SpringerLink
Log in

Stem-cell transplantation for the treatment of advanced solid tumors

  • Original Paper
  • Published:
Springer Seminars in Immunopathology Aims and scope Submit manuscript

Abstract

Over the past two decades, high-dose chemotherapy (HDC) with autologous stem-cell transplantation (ASCT) has been explored for a variety of solid tumors in adults, particularly breast cancer, ovarian cancer and non-seminomatous germ-cell tumors. The results of prospective phase II studies seemed superior in many cases to the outcome expected with standard-dose chemotherapy (SDC). The value of HDC for adult solid tumors remains, in most instances, a controversial issue, currently under the scrutiny of randomized phase III trial evaluation. ASCT pursuing an immune graft-versus-tumor effect has been evaluated in recent years for patients with advanced and refractory solid malignancies. This article reviews the results of the main phase II and III studies of HDC with ASCT, as well as the preliminary experience using allogeneic transplantation for solid tumors.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Anderson IC, Shpall EJ, Leslie DS, et al (1989) Elimination of malignant clonogenic breast cancer cells from human bone marrow. Cancer Res 15:4659

    Google Scholar 

  2. Antman K, Ayash L, Elias A, et al (1992) A phase II study of high-dose cyclophosphamide, thiotepa, and carboplatin with autologous bone marrow support in women with measurable advanced breast cancer responding to standard-dose therapy. J Clin Oncol 10:102

    Google Scholar 

  3. Antman KH, Rowlings PA, Vaughan WP, et al (1997) High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America. J Clin Oncol 15:1870

    Google Scholar 

  4. Ariel IM, Pack GT (1962) Treatment of disseminated melanoma with phenylalanine mustard (melphalan) and autogenous bone marrow transplants. Surgery 51:582

    Google Scholar 

  5. Ayash LJ, Elias A, Wheeler C, et al (1994) Double dose-intensive chemotherapy with autologous marrow and peripheral-blood progenitor-cell support for metastatic breast cancer: a feasibility study. J Clin Oncol 12:37

    Google Scholar 

  6. Ayash LJ, Elias A, Schwartz G, et al (1996) Double dose-intensive chemotherapy with autologous stem-cell support for metastatic breast cancer: No improvement in progression-free survival by the sequence of high-dose melphalan followed by cyclophosphamide, thiotepa, and carboplatin. J Clin Oncol 14:2984

    Google Scholar 

  7. Ayash L, Elias A, Ibrahim J, et al (1998) High-dose multimodality therapy with autologous stem cell support for stage IIIB breast cancer. J Clin Oncol 16:1000

    Google Scholar 

  8. Basser R, O’Neill A, Martinelli G, et al (2003 ) Randomized trial comparing up-front, multi-cycle dose-intensive chemotherapy (CT) versus standard dose CT in women with high-risk stage 2 or 3 breast cancer (BC): first results from IBCSG trial 15–95. Proc Am Soc Clin Oncol 22:6a (abstr 20)

    Google Scholar 

  9. Bay JO, Fleury J, Choufi B, et al (2002) Allogeneic hematopoietic stem cell transplantation in ovarian carcinoma: results of five patients. Bone Marrow Transplant 30:95

    Google Scholar 

  10. Bearman SI, Overmoyer BA, Bolwell BJ, et al (1997) High-dose chemotherapy with autologous peripheral blood progenitor cell support for primary breast cancer in patients with 4–9 involved axillary lymph nodes. Bone Marrow Transplant 20:931

    Google Scholar 

  11. Ben-Yosef R, Or R, Nagler A, Slavin S (1996) Graft-versus-tumour and graft-versus-leukaemia effect in patient with concurrent breast cancer and acute myelocytic leukaemia. Lancet 348:1242

    Google Scholar 

  12. Bergh J, Wiklund T, Erikstein B, et al (2000) Tailored fluoruracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial. Lancet 356:1384

    Google Scholar 

  13. Bertucci F, Viens P, Delpero JR, et al (2000) High-dose melphalan-based chemotherapy and autologous stem cell transplantation after second look laparotomy in patients with chemosensitive advanced ovarian carcinoma: long-term results. Bone Marrow Transplant 26:61

    Google Scholar 

  14. Bertuzzi A, Castagna L, Nozza A, et al (2002) High-dose chemotherapy in poor-prognosis adult small round-cell tumors: clinical and molecular results from a prospective study. J Clin Oncol 20:2181

    Google Scholar 

  15. Bertuzzi A, Castagna L, Quagliuolo V, et al (2003) Prospective study of high-dose chemotherapy and autologous peripheral stem cell transplantation in adult patients with advanced desmoplastic small round-cell tumour. Br J Cancer 89:1159

    Google Scholar 

  16. Bewick M, Chadderton T, Conlon M, et al (1999) Expression of C-erbB-2/HER-2 in patients with metastatic breast cancer undergoing high-dose chemotherapy and autologous blood stem cell support. Bone Marrow Transplant 24:377

    Google Scholar 

  17. Bewick M, Conlon M, Parissenti AM, et al (2001) Soluble Fas (CD95) is a prognostic factor in patients with metastatic breast cancer undergoing high-dose chemotherapy and autologous stem cell transplantation. J Hematother Stem Cell Res 10:759

    Google Scholar 

  18. Beyer J, Kramar A, Mandanas R, et al (1996) High-dose chemotherapy as salvage treatment in germ cell tumors: a multivariate analysis of prognostic variables. J Clin Oncol 14:2638

    Google Scholar 

  19. Bhatia S, Abonour R, Porcu P, et al (2000) High-dose chemotherapy as initial salvage chemotherapy in patients with relapsed testicular experience. J Clin Oncol 18:3346

    Google Scholar 

  20. Biron P, Durand M, Roché H, et al (2002) High dose thiotepa (TTP), cyclophosphamide (CPM) and stem cell transplantation after 4 FEC 100 compared with 4 FEC alone allowed a better disease free survival but the same overall survival in first line chemotherapy for metastatic breast cancer. Results of the PEGASE 03 French protocol. Proc Am Soc Clin Oncol 21:42a (abstr 167)

    Google Scholar 

  21. Bishop MR, Marchigiani D, Grasmeder S, et al (2003) Demonstration of clinical responses to adoptive cellular therapy using allogeneic T cells in metastatic breast cancer. Proc Am Soc Clin Oncol 22:164a (abstr 657)

    Google Scholar 

  22. Blaise D, Bay JO, Faucher C, et al (2004) Reduced-intensity preparative regimen and allogeneic stem cell transplantation for advanced solid tumors. Blood 103:435

    Google Scholar 

  23. Blay JY, Bouhour D, Ray-Coquard I, et al (2000) High-dose chemotherapy with autologous hematopoietic stem-cell transplantation for advanced soft tissue sarcoma in adults. J Clin Oncol 18:3643

    Google Scholar 

  24. Bokemeyer C, Kollmannsberger C, Meisner C, et al (1999) First-line high-dose chemotherapy compared with standard-dose PEB/VIP chemotherapy in patients with advanced germ cell tumors: a multivariate and matched-pair analysis. J Clin Oncol 17:3450

    Google Scholar 

  25. Bregni M, Dodero A, Peccatori J, et al (2002) Nonmyeloablative conditioning followed by hematopoietic cell allografting and donor lymphocyte infusions for patients with metastatic renal and breast cancer. Blood 99:4234

    Google Scholar 

  26. Brenner MK, Rill DR, Moen RC, et al (1993) Gene-marking to trace origin of relapse after autologous bone marrow transplantation. Lancet 341:85

    Google Scholar 

  27. Broun ER, Nichols CR, Kneebone P, et al (1992) Long-term outcome of patients with relapsed and refractory germ cell tumors treated with high-dose chemotherapy and autologous bone marrow rescue. Ann Intern Med 117:124

    Google Scholar 

  28. Broun ER, Nichols CR, Turns M, et al (1994) Early salvage therapy for germ cell cancer using high dose chemotherapy with autologous bone marrow support. Cancer 73:1716

    Google Scholar 

  29. Broun ER, Sridhara R, Sledge GW, et al (1995) Tandem autotransplantion for the treatment of metastatic breast cancer. J Clin Oncol 13:2050

    Google Scholar 

  30. Broun ER, Nichols CR, Gize G, et al (1997) Tandem high dose chemotherapy with autologous bone marrow transplantation for initial relapse of testicular germ cell cancer. Cancer 79:1605

    Google Scholar 

  31. Brugger W, Fetscher S, Hasse J, et al (1998) Multimodality treatment including early high-dose chemotherapy with peripheral blood stem cell transplantation in limited-disease small cell lung cancer. Semin Oncol 25 (Suppl 2):42

    Google Scholar 

  32. Burdach S, Kaick B van, Laws HJ, et al (2000) Allogeneic and autologous stem-cell transplantation in advanced Ewing tumors. An update after long-term follow-up from two centers of the European Intergroup study EICESS. Ann Oncol 11:1451

    Google Scholar 

  33. Burdach S, Jurgens H (2002) High-dose chemoradiotherapy (HDC) in the Ewing family of tumors (EFT). Crit Rev Oncol Hematol 41:169

    Google Scholar 

  34. Burdach S, Meyer-Bahlburg A, et al (2003) High-dose therapy for patients with primary multifocal and early relapsed Ewing’s tumors: results of two consecutive regimens assessing the role of total-body irradiation. J Clin Oncol 21:3072

    Google Scholar 

  35. Cagnoni PJ, Nieto Y, Shpall EJ, et al (1998) High-dose chemotherapy with autologous progenitor cell support as part of combined modality therapy for inflammatory breast cancer. J Clin Oncol 16:1661

    Google Scholar 

  36. Chevreau C, Droz JP, Pico JL, et al (1993) Early intensified chemotherapy with autologous bone marrow transplantation in first line treatment of poor risk non-seminomatous germ cell tumors. Eur Urol 23:213

    Google Scholar 

  37. Childs R, Chernoff A, Contentin N, et al (2000) Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med 343:750

    Google Scholar 

  38. Cornbleet MA, McElwain TJ, Kumar PJ, et al (1990) Treatment of advanced malignant melanoma with high-dose melphalan and autologous bone marrow transplantation. Br J Cancer 61:330

    Google Scholar 

  39. Crown JP, Lind M, Gould A, et al (2002) High-dose chemotherapy (HDC) with autograft (PBP) support is not superior to cyclophosphamide (CPA), methotrexate and 5-FU (CMF) following doxorubicin (D) induction in patients (pts) with breast cancer and 4 or more involved axillary lymph nodes (4+ LN): The Anglo-Celtic I study. Proc Am Soc Clin Oncol 21:42a (abstr 166)

    Google Scholar 

  40. Crown, J, Perey L, Lind M, et al (2003) Superiority of tandem high-dose chemotherapy (HDC) versus optimized conventionally-dosed chemotherapy (CDC) in patients (pts) with metastatic breast cancer (MBC): The International Breast Cancer Dose Intensity Study (IBDIS 1). Proc Am Soc Clin Oncol 22:23a (abstr 88)

    Google Scholar 

  41. Crump M, Gluck S, Stewart D, et al (2001) A randomized trial of high-dose chemotherapy (HDC) with autologous peripheral blood stem cell support (AHPCT) compared to standard chemotherapy in women with metastatic breast cancer: A National Cancer Institute of Canada (NCIC) Clinical Trials Group study. Proc Am Soc Clin Oncol 20:21a (abstr 82)

    Google Scholar 

  42. Curé H, Battista C, Guastalla J, et al (2001) Phase III randomized trial of high-dose chemotherapy (HDC) and peripheral blood stem cell (PBSC) support as consolidation in patients with responsive low-burden advanced ovarian cancer: Preliminary results of a GINECO/FNCLCC/SFGM-TC study. Proc Am Soc Clin Oncol 20:204a (abstr 815)

    Google Scholar 

  43. Damon LE, Wolf JL, Rugo HS, et al (2002) Long follow-up of patients with primary breast cancer and ≥10 involved axillary lymph nodes after high-dose chemotherapy and autologous stem cell transplant. Biol Blood Marrow Transplant 8:71a (abstr 37)

    Google Scholar 

  44. Deisseroth AB, Zu Z, Claxton D, et al (1994) Genetic marking shows that Ph+ cells present in autologous transplants of chronic myelogenous leukemia contribute to relapse after autologous bone marrow transplant in CML. Blood 83:3068

    Google Scholar 

  45. Dunphy FR, Spitzer G, Buzdar AU, et al (1990) Treatment of estrogen receptor-negative or hormonally refractory breast cancer with double high-dose chemotherapy intensification and bone marrow support. J Clin Oncol 8:1207

    Google Scholar 

  46. Durando X, Lemaire JJ, Tortochaux J, et al (2003) High-dose BCNU followed by autologous hematopoietic stem cell transplantation in supratentorial high-grade malignant gliomas: a retrospective analysis of 114 patients. Bone Marrow Transplant 31:559

    Google Scholar 

  47. Eder JP, Antman K, Peters WP, et al (1986) High dose combination alkylating agent chemotherapy with autologous bone marrow support for metastatic breast cancer. J Clin Oncol 4:646

    Google Scholar 

  48. Eibl B, Schwaighofer H, Nachbaur D, et al (1996) Evidence for a graft-versus-tumor effect in a patient treated with marrow ablative chemotherapy and allogeneic bone marrow transplantation for breast cancer. Blood 88:1501

    Google Scholar 

  49. Einhorn LH (2002) Curing metastatic testicular cancer. Proc Natl Acad Sci USA 99:4592

    Google Scholar 

  50. Elias AD, Ayash LJ, Wheeler C, et al (1995) Phase I study of high-dose ifosfamide, carboplatin and etoposide with autologous hematopoietic stem cell support. Bone Marrow Transplant 15:373

    Google Scholar 

  51. Elias AD, Ibrahim J, Skarin AT, et al (1999) Dose-intensive therapy for limited-stage small-cell lung cancer: long-term outcome. J Clin Oncol 17:1175

    Google Scholar 

  52. Elias AD, Ibrahim J, Richardson P, et al (2002) The impact of induction duration and the number of high-dose cycles on the long-term survival of women with metastatic breast cancer treated with high-dose chemotherapy with stem cell rescue: an analysis of sequential phase I/II trials from the Dana Farber/Beth Israel STAMP program. Biol Blood Marrow Transplant 8:198

    Google Scholar 

  53. Elias AD, Skarin AT, Richardson P, et al (2002) Dose-intensive therapy for extensive-stage small cell lung cancer and extrapulmonary small cell carcinoma: long-term outcome. Biol Blood Marrow Transplant 8:326

    Google Scholar 

  54. Farha P, Spitzer G, Valdivieso M, et al (1983) High-dose chemotherapy and autologous bone marrow transplantation for the treatment of small-cell lung carcinoma. Cancer 52:1351

    Google Scholar 

  55. Farquhar C, Basser R, Hetrick S, et al (2003) High dose chemotherapy and autologous bone marrow or stem cell transplantation versus conventional chemotherapy for women with metastatic breast cancer. Cochrane Database Syst Rev (1): CD003142 (http://www.cochrane.org/cochrane/revabstr/AB003142.htm)

  56. Farquhar C, Basser R, Marjoribanks J, Lethaby A (2003) High dose chemotherapy and autologous bone marrow or stem cell transplantation versus conventional chemotherapy for women with early poor prognosis breast cancer. Cochrane Database Syst Rev (1): CD003139, (http://www.cochrane.org/cochrane/revabstr/AB003139.htm)

  57. Fetscher S, Brugger W, Engelhardt R, et al (1999) Standard- and high-dose etoposide, ifosfamide, carboplatin, and epirubicin in 100 patients with small-cell lung cancer: a mature follow-up report. Ann Oncol 10:561

    Google Scholar 

  58. Gianni AM, Siena S, Bregni M, et al (1997) Efficacy, toxicity and applicability of high-dose chemotherapy as adjuvant treatment in operable breast cancer with 10 or more involved axillary nodes: five-year results. J Clin Oncol 15:2312

    Google Scholar 

  59. Gianni A, Bonadonna G (2001) Five-year results of the randomized clinical trial comparing standard versus high-dose myeloablative chemotherapy in the adjuvant treatment of breast cancer with >3 positive nodes (LN+). Proc Am Soc Clin Oncol 20:21a (abstr 80)

    Google Scholar 

  60. Goodwin W, Crowley J (1989) A retrospective comparison of high-dose BCNU with autologous marrow rescue plus radiotherapy vs IV BCNU plus radiation therapy in high grade gliomas. Proc Am Soc Clin Oncol 8:90

    Google Scholar 

  61. Harlin H, Artz AS, Mahowald M, et al (2004) Clinical responses following nonmyeloablative allogeneic stem cell transplantation for renal cell carcinoma are associated with expansion of CD8(+) IFN-gamma-producing T cells. Bone Marrow Transplant 33:491

    Google Scholar 

  62. Herzig R, Phillips G, Wolff S, et al (1984) Treatment of metastatic melanoma with intensive melphalan-BCNU combination chemotherapy and cryopreserved autologous bone marrow transplantation. Proc Am Soc Clin Oncol 3:264

    Google Scholar 

  63. Hu WW, Negrin RS, Stockerl-Goldstein K, et al (2000) Four-cycle high-dose therapy with hematopoietic support for metastatic breast cancer: No improvement in outcomes compared with single-course high-dose therapy. Biol Blood Marrow Transplant 6:58

    Google Scholar 

  64. Humblet Y, Symann M, Bosly A, et al (1987) Late intensification chemotherapy with autologous bone marrow transplantation in selected small-cell carcinoma of the lung: a randomized study. J Clin Oncol 5:1864

    Google Scholar 

  65. Johnson DB, Thompson JM, Corwin JA, et al (1987) Prolongation of survival for high-grade malignant gliomas with adjuvant high-dose BCNU and autologous bone marrow transplantation. J Clin Oncol 5:783

    Google Scholar 

  66. Jones RB, Shpall EJ, Ross M, et al (1990) AFM induction chemotherapy followed by intensive alkylating agent consolidation with autologous bone marrow support (ABMS) for advanced breast cancer: current results. Proc Am Soc Clin Oncol 7:121

    Google Scholar 

  67. Jung U, Foley JE, Erdmann AA, et al (2003) CD3/CD28-costimulated T1 and T2 subsets: differential in vivo allosensitization generates distinct GVT and GVHD effects. Blood 102:3439

    Google Scholar 

  68. Kessinger A, Petersen K, Bishop M, Schmit-Pokorny K (1994) High dose therapy with autologous hematopoietic stem cell rescue for patients with metastatic soft tissue sarcoma. Proc Am Soc Clin Oncol 13:A1674

    Google Scholar 

  69. Kim YS, Konoplev SN, Montemurro F, et al (2001) HER-2/neu overexpression as a poor prognostic factor for patients with metastatic breast cancer undergoing high-dose chemotherapy with autologous stem cell transplantation. Clin Cancer Res 7:4008

    Google Scholar 

  70. Kolb EA, Kushner BH, Gorlick R, et al (2003) Long-term event-free survival after intensive chemotherapy for Ewing’s family of tumors in children and young adults. J Clin Oncol 21:3423

    Google Scholar 

  71. Krause DS, Fackler MJ, Civin CI, May WS (1996) CD34: structure, biology and clinical utility. Blood 87:1

    Google Scholar 

  72. Laport GF, Grad G, Grinblatt DL, Bitran JD, Williams SF (1998) High-dose chemotherapy consolidation with autologous stem cell rescue in metastatic breast cancer: a 10-year experience. Bone Marrow Transplant 21:127

    Google Scholar 

  73. Ledermann JA, Herd R, Maraninchi D, et al (2001) High-dose chemotherapy for ovarian carcinoma: long-term results from the Solid Tumour Registry of the European Group for Blood and Marrow Transplantation (EBMT). Ann Oncol 12:693

    Google Scholar 

  74. Legros M, Dauplat J, Fleury J, et al (1997) High-dose chemotherapy with hematopoietic rescue in patients with stage III to IV ovarian cancer: long-term results, J Clin Oncol 15:1302

    Google Scholar 

  75. Leyvraz S, Perey L, Rosti G, et al (1999) Multiple courses of high-dose ifosfamide, carboplatin, and etoposide with peripheral-blood progenitor cells and filgrastim for small-cell lung cancer: a feasibility study by the European Group for Blood and Marrow Transplantation. J Clin Oncol 17:3531

    Google Scholar 

  76. Lister J, Rybka WB, Donnenberg AD, et al (1995) Autologous peripheral blood stem cell transplantation and adoptive immunotherapy with activated natural killer cells in the immediate post-transplant period. Clin Cancer Res 1:607

    Google Scholar 

  77. Lotz J-P, Curé H, Janvier M, et al (1999) Intensive chemotherapy and autograft of hematopoietic stem cells in the treatment of metastatic breast cancer: results of the national protocol PEGASE 04 (in French). Hematol Cell Ther 41:71

    Google Scholar 

  78. Madan B, Broadwater G, Rubin P, et al (2000) Improved survival with consolidation high-dose cyclophosphamide, cisplatin and carmustine (HD-CPB) compared with observation in women with metastatic breast cancer (MBC) and only bone metastases treated with induction adriamycin, 5-fluorouracil and methotrexate (AFM): a phase III prospective randomized comparative trial. Proc Am Soc Clin Oncol 19:48a

    Google Scholar 

  79. Margolin K, Doroshow JH, Ahn C, et al (1996) Treatment of germ cell cancer with two cycles of high-dose ifosfamide, carboplatin, and etoposide with autologous stem-cell support. J Clin Oncol 14:2631

    Google Scholar 

  80. Meisenberg BR, Ross M, Vredenburgh JJ, et al (1994) Randomized trial of high-dose chemotherapy with autologous bone marrow support as adjuvant therapy for high-risk multi-node-positive malignant melanoma. J Natl Cancer Inst 85:1080

    Google Scholar 

  81. Mena O, Igarashi T, Srinivasan R, et al (2001) Immunologic mechanisms involved in the graft-vs-tumor (GVT) effect in renal cell carcinoma (RCC) following nonmyeloablative allogeneic peripheral blood stem cell transplantation (NST). Blood 98:856a (abstr 3555)

    Google Scholar 

  82. Mohr M, Hilgenfeld E, Fietz B, et al (1999) Efficacy and safety of simultaneous immunomagnetic CD34+ cell selection and breast cancer cell purging in peripheral blood progenitor cell samples used for hematopoietic rescue after high-dose therapy. Clin Cancer Res 5:1035

    Google Scholar 

  83. Motzer RJ, Gulati SC, Crown JP, et al (1992) High-dose chemotherapy and autologous bone marrow rescue for patients with refractory germ cell tumors. Cancer 69:550

    Google Scholar 

  84. Motzer RJ, Mazumdar M, Gulati SC, et al (1993) Phase II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors. J Natl Cancer Inst 85:1828

    Google Scholar 

  85. Motzer RJ, Mazumdar M, Bosl GJ, et al (1996) High-dose carboplatin, etoposide, and cyclophosphamide for patients with refractory germ cell tumors: treatment results and prognostic factors for survival and toxicity. J Clin Oncol 14:1098

    Google Scholar 

  86. Motzer RJ, Mazumdar M, Bajorin DF, et al (1997) High-dose carboplatin, etoposide, and cyclophosphamide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors. J Clin Oncol 15:2546

    Google Scholar 

  87. Negrin RS, Atkinson K, Leemhuis T, et al (2000) Transplantation of highly purified CD34+ Thy-1+ hematopoietic stem cells in patients with metastatic breast cancer. Biol Blood Marrow Transplant 6:262

    Google Scholar 

  88. Negrier S, Escudier B, Lasset C, et al (1998) Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Français d’Immunotherapie. N Engl J Med 338:1272

    Google Scholar 

  89. Nichols CR, Tricot G, Williams SD, et al (1989) Dose-intensive chemotherapy in refractory germ cell cancer: a phase I/II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation. J Clin Oncol 7:932

    Google Scholar 

  90. Nichols CR, Andersen J, Lazarus HM, et al (1992) High-dose carboplatin and etoposide with autologous bone marrow transplantation in refractory germ cell cancer: an Eastern Cooperative Oncology Group protocol. J Clin Oncol 10:558

    Google Scholar 

  91. Nieto Y, Cagnoni PJ, Shpall EJ, et al (1999) Phase II trial of high-dose chemotherapy with autologous stem cell transplant for stage IV patients with minimal metastatic disease. Clin Cancer Res 5:1731

    Google Scholar 

  92. Nieto Y, Cagnoni PJ, Xu X, et al (1999) Predictive model for relapse after high-dose chemotherapy with peripheral blood progenitor cell support for high-risk primary breast cancer. Clin Cancer Res 5:3425

    Google Scholar 

  93. Nieto Y, Cagnoni PJ, Nawaz S, et al (2000) Evaluation of the predictive value of HER2/neu overexpression and p53 mutations in high-risk primary breast cancer patients treated with high-dose chemotherapy and autologous stem-cell transplantation. J Clin Oncol 18:2070

    Google Scholar 

  94. Nieto Y, Champlin RE, Wingard JR, et al (2000) Status of high-dose chemotherapy for breast cancer: a review. Biol Blood Marrow Transplant 6:476

    Google Scholar 

  95. Nieto Y, Cagnoni PJ, Shpall EJ, et al (2000) Phase I trial of docetaxel (DTX) combined with fixed doses of melphalan and carboplatin, with peripheral blood progenitor cell (PBPC) support in refractory malignancies. Proc Am Soc Clin Oncol 19:56a

    Google Scholar 

  96. Nieto Y, Nawaz S, Jones RB, et al (2002) Prognostic model for relapse after high-dose chemotherapy with autologous stem-cell transplantation for stage IV oligometastatic breast cancer. J Clin Oncol 20:707

    Google Scholar 

  97. Nieto Y, Nawaz S, Shpall EJ, et al (2004) Long-term analysis and prospective validation of a prognostic model for patients with high-risk primary breast cancer receiving high-dose chemotherapy. Clin Cancer Res 10:2609

    Google Scholar 

  98. Nieto Y, Franklin WA, Jones RB, et al (2004) Prognostic significance of occult tumor cells in the apheresis products of patients with advanced breast cancer receiving high-dose chemotherapy and autologous hematopoietic progenitor cell support. Biol Blood Marrow Transplant 10:415

    Google Scholar 

  99. Nieto Y, Rosinski S, Nawaz S, et al (2004) Prognostic evaluation of the early lymphocyte recovery in patients with advanced metastatic and non-metastastic breast cancer receiving high-dose chemotherapy with an autologous stem-cell transplant. Clin Cancer Res (in press)

  100. Nieto Y, Vredenburgh JJ, Shpall EJ, et al (2004) Pilot study of concurrent administration of trastuzumab with high-dose cyclophosphamide, cisplatin, and BCNU, with autologous hematopoietic progenitor-cell support, in patients with advanced HER2-positive breast cancer. Clin Cancer Res (in press)

  101. Nikcevich DA, Vredenburgh JJ, Broadwater G, et al (2002) Ten year follow-up after high-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. Proc Am Soc Clin Oncol 21:415a

    Google Scholar 

  102. Nitz UA, Frick M, Mohrmann S, et al (2003) Tandem high dose chemotherapy versus dose-dense conventional chemotherapy for patients with high risk breast cancer: Interim results from a multicenter phase III trial. Proc Am Soc Clin Oncol 22:832a (abstr 3344)

    Google Scholar 

  103. Pecora AL, Lazarus HM, Jennis AA, et al (2003) Breast cancer cell contamination of blood stem cell products in patients with metastatic breast cancer: predictors and clinical relevance. Biol Blood Marrow Transplant 8:536

    Google Scholar 

  104. Pedrazzoli P, Da Prada GA, Giorgiani G, et al (2002) Allogeneic blood stem cell transplantation after a reduced-intensity, preparative regimen: a pilot study in patients with refractory malignancies. Cancer 94:2409

    Google Scholar 

  105. Peters WP, Eder JP, Henner WD, et al (1986) High-dose combination chemotherapy with autologous bone marrow support: a phase I trial. J Clin Oncol 4:646

    Google Scholar 

  106. Peters WP, Shpall EJ, Jones RB, et al (1988) High-dose combination chemotherapy with bone marrow support as initial treatment for metastatic breast cancer. J Clin Oncol 6:1368

    Google Scholar 

  107. Peters WP, Jones RB, Vredenburgh J, et al (1996) A large, prospective, randomized trial of high-dose combination alkylating agents (CPB) with autologous cellular support (ABMS) as consolidation for patients with metastatic breast cancer achieving complete remission after intensive doxorubicin-based induction therapy (AFM). Proc Am Soc Clin Oncol 15:121a

    Google Scholar 

  108. Peters WP, Ross M, Vredenburgh JJ, et al (1993) High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. J Clin Oncol 11:1132

    Google Scholar 

  109. Peters WP, Rosner G, Vredenburgh J, et al (2001) Updated results of a prospective, randomized comparison of two doses of combination alkylating agents (AA) as consolidation after CAF in high-risk primary breast cancer involving ten or more axillary lymph nodes (LN): CALGB 9082/SWOG 9114/NCIC Ma-13. Proc Am Soc Clin Oncol 20:21a

    Google Scholar 

  110. Phillips GL, Fay JW, Herzig GP, et al (1982) A phase I-II study; intensive BCNU (1,3-bis (2-chloroethyl)-1-nitrosourea, NSC 409962) and autologous bone marrow transplantation for refractory cancer. Cancer 52:1792

    Google Scholar 

  111. Phillips GL, Wolff SN, Fay JW, et al (1986) Intensive BCNU chemotherapy and autologous bone marrow transplantation for malignant glioma. J Clin Oncol 4:639

    Google Scholar 

  112. Porrata LF, Ingle JN, Litzow MR, et al (2001) Prolonged survival associated with early lymphocyte recovery after autologous hematopoietic stem cell transplantation for patients with metastatic breast cancer. Bone Marrow Transplant 28:865

    Google Scholar 

  113. Rick O, Bokemeyer C, Beyer J, et al (2001) Salvage treatment with paclitaxel, ifosfamide, and cisplatin plus high-dose carboplatin, etoposide, and thiotepa followed by autologous stem-cell rescue in patients with relapsed or refractory germ cell cancer. J Clin Oncol 19:81

    Google Scholar 

  114. Rini BI, Zimmerman T, Stadler WM, et al (2002) Allogeneic stem-cell transplantation of renal cell cancer after nonmyeloablative chemotherapy: feasibility, engraftment, and clinical results. J Clin Oncol 20:2017

    Google Scholar 

  115. Rizzieri DA, Vredenburgh JJ, Jones R, et al (1999) Prognostic and predictive factors for patients with metastatic breast cancer undergoing aggressive induction therapy followed by high-dose chemotherapy with autologous stem-cell support. J Clin Oncol 17:3064

    Google Scholar 

  116. Rizzieri DA, Long GD, Vredenburgh JJ, et al (2001) Non-myeloablative allogeneic transplantation using T depleted matched sibling peripheral blood stem cells. Blood 98:420a (abstr 1764)

    Google Scholar 

  117. Roché, HH, Pouillart P, Meyer N, et al (2001 ) Adjuvant high dose chemotherapy (HDC) improves early outcome for high risk (N>7) breast cancer patients: the PEGASE 01 trial. Proc Am Soc Clin Oncol 20:27a (abstr 102)

    Google Scholar 

  118. Rodenhuis S, Westermann A, Holtkamp MJ, et al (1996) Feasibility of multiple courses of high-dose cyclophosphamide, thiotepa, and carboplatin for breast cancer or germ cell cancer. J Clin Oncol 14:1473

    Google Scholar 

  119. Rodenhuis S, Bontenbal M, Beex LVAM, et al (2003) High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer. N Engl J Med 349:7

    Google Scholar 

  120. Rosenberg SA, Lotze MT, Muul LM, et al (1985) Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 313:1485

    Google Scholar 

  121. Ross AA, Cooper BW, Lazarus HM, et al (1993) Detection and viability of tumor cells in peripheral blood stem cell collections from breast cancer patients using immunocytochemical and clonogenic assay techniques. Blood 82:2605

    Google Scholar 

  122. Rosti G, Pico J-L, Wandt H, et al (2002) High-dose chemotherapy (HDC) in the salvage treatment of patients failing first-line platinum chemotherapy for advanced germ cell tumors (GCT): first results of a prospective randomized trial of the European Group for Blood and Marrow Transplantation (EBMT): IT-94 study. Proc Am Soc Clin Oncol 21:180a (abstr 716)

    Google Scholar 

  123. Salerno MG, Ferrandina G, Greggi S, et al (2001) High-dose chemotherapy as a consolidation approach in advanced ovarian cancer: long-term results. Bone Marrow Transplant 27:1017

    Google Scholar 

  124. Schmid P, Samonigg H, Nitsch T, et al (2002) Randomized trial of up front tandem high-dose chemotherapy (HD) compared to standard chemotherapy with doxorubicin and paclitaxel (AT) in metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 21:43a (abstr 171)

    Google Scholar 

  125. Schmoll HJ, Kollmannsberger C, Metzner B, et al (2003) Long-term results of first-line sequential high-dose etoposide, ifosfamide, and cisplatin chemotherapy plus autologous stem cell support for patients with advanced metastatic germ cell cancer: an extended phase I/II study of the German Testicular Cancer Study Group. J Clin Oncol 21:4083

    Google Scholar 

  126. Shapiro CL, Ayash L, Webb IJ, et al (1997) Repetitive cycles of cyclophosphamide, thiotepa, and carboplatin intensification with peripheral-blood progenitor cells and filgrastim in advanced breast cancer patients. J Clin Oncol 15:674

    Google Scholar 

  127. Shea TC, Antman KH, Eder JP, et al (1988) Malignant melanoma: Treatment with high-dose combination alkylating agent chemotherapy and autologous bone marrow support. Arch Dermatol 124:878

    Google Scholar 

  128. Shpall EJ, Jones RB, Bast RC, et al (1991) 4-Hydroperoxycyclophosphamide purging of breast cancer from the mononuclear cell fraction of bone marrow in patients receiving high-dose chemotherapy and autologous marrow support: a phase I trial. J Clin Oncol 9:85

    Google Scholar 

  129. Shpall EJ, Bast RC, Joines WT, et al (1991) Immunomagnetic purging of breast cancer from bone marrow for autologous transplantation. Bone Marrow Transplant 7:145

    Google Scholar 

  130. Shpall EJ, Jones RB, Bearman SI, et al (1994) Transplantation of enriched CD34-positive autologous marrow into breast cancer patients following high-dose chemotherapy: influence of CD34-positive peripheral-blood progenitors and growth factors on engraftment. J Clin Oncol 12:28

    Google Scholar 

  131. Siegert W, Beyer J, Strohscheer I, et al (1994) High-dose treatment with carboplatin, etoposide and ifosfamide followed by autologous stem-cell transplantation in relapsed or refractory germ cell cancer: a phase I/II study. J Clin Oncol 12:1223

    Google Scholar 

  132. Solano C, Badia B, Lluch A, et al (2001) Prognostic significance of the immunocytochemical detection of contaminating tumor cells (CTC) in apheresis products of patients with high-risk breast cancer treated with high-dose chemotherapy and stem cell transplantation. Bone Marrow Transplant 27:287

    Google Scholar 

  133. Somlo G, Doroshow JH, Forman SJ, et al (1997) High-dose chemotherapy and stem-cell rescue in the treatment of high-risk breast cancer: prognostic indicators of progression-free and overall survival. J Clin Oncol 15:2882

    Google Scholar 

  134. Somlo G, Simpson JF, Frankel P, et al (2002) Predictors of long-term outcome following high-dose chemotherapy in high-risk primary breast cancer. Br J Cancer 87:281

    Google Scholar 

  135. Souhami RL, Harper PG, Linch D, et al (1983) High-dose cyclophosphamide with autologous bone marrow transplantation for small-cell lung carcinoma of the bronchus. Cancer Chemother Pharmacol 10:205

    Google Scholar 

  136. Souhami RL, Finn G, Gregory WM, et al (1985) High-dose cyclophosphamide in small-cell carcinoma of the lung. J Clin Oncol 3:958

    Google Scholar 

  137. Souhami RL, Hajichristou HT, Miles DW, et al (1989) Intensive chemotherapy with autologous bone marrow transplantation for small-cell lung cancer. Cancer Chemother Pharmacol 24:321

    Google Scholar 

  138. Spitzer G, Farha P, Valdivieso M, et al (1986) High-dose intensification therapy with autologous bone marrow support for limited small-cell bronchogenic carcinoma. J Clin Oncol 4:4

    Google Scholar 

  139. Stadtmauer EA, O’Neill A, Goldstein LJ, et al (2000) Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. N Engl J Med 342:1069

    Google Scholar 

  140. Stiff PJ, Bayer R, Kerger C, et al (1997) High-dose chemotherapy with autologous transplantation for persistent/relapsed ovarian cancer: a multivariate analysis of survival for 100 consecutively treated patients. J Clin Oncol 15:1309

    Google Scholar 

  141. Stiff PJ, Veum-Stone J, Lazarus HM, et al (2000) High-dose chemotherapy and autologous stem-cell transplantation for ovarian cancer: an autologous blood and marrow transplant registry report. Ann Intern Med 133:504

    Google Scholar 

  142. Takvorian T, Parker LM, Hochberg FH, Canellos GP (1983) Autologous bone marrow transplantation: host effects of high-dose BCNU. J Clin Oncol 1:610

    Google Scholar 

  143. Tallman M, Gray R, Robert N, et al (2003) Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation in high-risk breast cancer. N Engl J Med 349:17

    Google Scholar 

  144. Thatcher D, Lind M, Morgenstern G, et al (1989) High-dose double alkylating agent chemotherapy with DTIC, melphalan, or ifosfamide and marrow rescue for metastatic malignant melanoma. Cancer 63:1296

    Google Scholar 

  145. Ueno NT, Rondón G, Mirza NQ, et al (1998) Allogeneic peripheral-blood progenitor-cell transplantation for poor-risk patients with metastatic breast cancer. J Clin Oncol 16:986

    Google Scholar 

  146. Ueno NT, Rizzo JD, Hegenbart U, et al (2003) International Bone Marrow Transplant Registry/The European Group for Blood and Marrow Transplantation (IBMTR/EBMT) review of allogeneic hematopoietic stem-cell transplantation (ALLO HSCT) in metastatic breast cancer. Proc Annu Meet Am Soc Clin Oncol 22:832a (abstr 3345) (http://www.asco.org/ac/1,1003,_12–002511–00_18–0023–00_19–003366–00_21–0015,00.asp)

  147. Ueno NT, Cheng YC, Rondon G, et al (2003) Rapid induction of complete donor chimerism by the use of a reduced-intensity conditioning regimen composed of fludarabine and melphalan in allogeneic stem cell transplantation for metastatic solid tumors. Blood 102:3829

    Google Scholar 

  148. Vahdat L, Balmaceda C, Papadopoulos K, et al (2002) Phase II trial of sequential high-dose chemotherapy with paclitaxel, melphalan, and cyclophosphamide, thiotepa, and carboplatin with peripheral blood progenitor support in women with responding metastatic breast cancer. Bone Marrow Transplant 30:149

    Google Scholar 

  149. Viens P, Gravis G, Blaise D, et al (1995) High dose chemotherapy with bone marrow rescue for patients with FIGO stage III or IV common epithelial ovarian carcinoma responding to first line treatment. Proc Annu Meet Am Soc Clin Oncol 14:A811

  150. Wolff SN, Herzig RH, Fay JW, et al (1989) High-dose thiotepa with autologous bone marrow transplantation for metastatic malignant melanoma: results of phase I and II studies of the North American Bone Marrow Transplantation Group. J Clin Oncol 7:245

    Google Scholar 

  151. Yanovich S, Mitsky P, Cornetta K, et al (2000) Transplantation of CD34+ peripheral blood cells selected using a fully automated immunomagnetic system in patients with high-risk breast cancer: results of a prospective randomized multicenter clinical trial. Bone Marrow Transplant 25:1165

    Google Scholar 

  152. Zander AR, Krüger W, Kröger N, et al (2002) High-dose chemotherapy with autologous hematopoietic stem-cell support (HSCS) vs standard-dose chemotherapy in breast cancer patients with 10 or more positive lymph nodes: first results of a randomized trial. Proc Am Soc Clin Oncol 21:415a (abstr 1658)

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of Colorado Health Sciences Center, 4200 East Ninth Avenue, B-190, Denver, CO, 80262, USA

    Yago Nieto

  2. MD Anderson Cancer Center, University of Texas, Houston, TX 77030, USA

    Roy B Jones & Elizabeth J Shpall

Authors
  1. Yago Nieto
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Roy B Jones
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Elizabeth J Shpall
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yago Nieto.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nieto, Y., Jones, R.B. & Shpall, E.J. Stem-cell transplantation for the treatment of advanced solid tumors. Springer Semin Immun 26, 31–56 (2004). https://doi.org/10.1007/s00281-004-0160-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00281-004-0160-8

Keywords

Search

Navigation